NVO - With Bumper $33B Sales Novo Nordisk Forecasts Double-Digit 2024 Earnings Growth Boosts Lower Dose Wegovy US Supplies | Benzinga

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported fourth quarter of 2023 sales of DKK 65.86 billion ($9.5 billion compared to the consensus of $8.82 billion), up 37% measured in Danish kroner and 43% at CER compared to 2022. 

Diabetes and Obesity care sales of DKK 61.29 billion drove the global sales growth of 43% at CER as GLP-1 diabetes sales increased by 62% at CER and Obesity care sales increased by 114% at CER. 

Wegovy sales totaled DKK 9.6 billion, slightly lower than the previous quarter and up 293% Y/Y. Ozempic sales increased 85% at Full story available on Benzinga.com